1. Robinson SI, Ahmed SK, Okuno SH, Arndt CA, Rose PS, Laack NN. Clinical outcomes of adult patients with relapsed Ewing sarcoma: a 30-year single-institution experience. Am J Clin Oncol. 2014;37(6):585-91.
2. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-14.
3. Ganjoo KN, Patel S. The treatment outcome for adult patients with Ewing's sarcoma. Curr Oncol Rep. 2013;15(4):372-7.
4. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J Clin Oncol. 2015;33(27):3036-46.
5. Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(33):4148-54.
6. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701.
7. Burgert EO, Jr., Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8(9):1514-24.
8. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006;47(1):22-9.
9. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27(15):2536-41.
10. Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract. 2016;12(3):208-16.
11. Bacci G, Ferrari S, Comandone A, Zanone A, Ruggieri P, Longhi A et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol. 2000;39(1):111-6.
12. Rodriguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer. 2007;110(2):375-84.
13. Orr WS, Denbo JW, Billups CA, Wu J, Navid F, Rao BN et al. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol. 2012;19(12):3816-22.
14. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19(6):1818-29.
15. Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer. 1993;53(3):371-6.
16. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115(15):3526-36.
17. Zhang J, Huang Y, Lu J, He A, Zhou Y, Hu H et al. Impact of first-line treatment on outcomes of Ewing sarcoma of the spine. Am J Cancer Res. 2018;8(7):1262-72.
18. Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(20):3284-91.
19. Tao HT, Hu Y, Wang JL, Cheng Y, Zhang X, Wang H et al. Extraskeletal Ewing sarcomas in late adolescence and adults: a study of 37 patients. Asian Pac J Cancer Prev. 2013;14(5):2967-71.
20. El Weshi A, Allam A, Ajarim D, Al Dayel F, Pant R, Bazarbashi S et al. Extraskeletal Ewing's sarcoma family of tumours in adults: analysis of 57 patients from a single institution. Clin Oncol (R Coll Radiol). 2010;22(5):374-81.
21. Ahmed SK, Robinson SI, Okuno SH, Rose PS, Issa Laack NN. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease. Am J Clin Oncol. 2014;37(5):423-9.
22. Seker MM, Kos T, Ozdemir N, Seker A, Aksoy S, Uncu D et al. Treatment and outcomes of Ewing sarcoma in Turkish adults: a single centre experience. Asian Pac J Cancer Prev. 2014;15(1):327-30.
23. Gupta AA, Pappo A, Saunders N, Hopyan S, Ferguson P, Wunder J et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010;116(13):3189-94.
24. Casey DL, Meyers PA, Alektiar KM, Magnan H, Healey JH, Boland PJ et al. Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol. 2014;113(2):248-53.
25. Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer. 2010;116(8):1964-73.
26. Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E et al. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother. 2014;26(1):49-56.
27. Diaz-Beveridge R, Lorente D, Torres B, Canete A, Rodrigo E, Bruixola G et al. Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience. J Pediatr Hematol Oncol. 2015;37(5):e278-84.
28. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors: Current scenario and unmet need. World journal of orthopedics. 2016;7(9):527-38.
29. Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? J Clin Oncol. 1997;15(7):2611-21.
30. Fizazi K, Dohollou N, Blay JY, Guerin S, Le Cesne A, Andre F et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998;16(12):3736-43.
31. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99-108.
32. Tahover E, Segal A, Isacson R, Rosengarten O, Grenader T, Gips M et al. Dexrazoxane added to doxorubicin-based adjuvant chemotherapy of breast cancer: a retrospective cohort study with a comparative analysis of toxicity and survival. Anticancer Drugs. 2017;28(7):787-94.
33. Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663-76.
34. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950-61.
35. Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S et al. Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group. J Clin Oncol. 2015;33(24):2639-45.